The FDA has greenlit Orca Bio’s allogeneic T cell–based immunotherapy to reduce graft-versus-host disease in patients being treated for blood cancers. Tregzi marks the first approval of a cell therapy using regulatory T cells, according to the biotech. Tregzi is also Orca’s first approved therapy, “validating the company’s high-precision platform and the potential of its pipeline,” the California-based company said in a Tuesday press release.